Post by
jeffm34 on Jul 24, 2021 10:48am
Research Capital Report
Price target of $5.00 US based on this:
Our valuation for Theratechnologies is based on a sum-of-the-parts methodology that factors in the company’s commercial segment and the NASH project,” he said. “To value TH’s commercial segment, we applied a 3.5x 2021 EV/Sales multiple to our 2021 total revenue estimate of US$72.7M discounted by 10% – equaling US$2.62/share. To value TH’s NASH project, we calculated a probability-adjusted NPV assuming a 15% success rate (was 10%) – equaling US$2.31/share.”
Comment by
jeffm34 on Jul 24, 2021 11:01am
https://www.cantechletter.com/2021/07/theratechnologies-keeps-bullish-target-at-research-capital/